Source: google_news
Source ID: gnews:b1d16195e8c5ffb4a08cea0d3e988303:IONS
URL: https://news.google.com/rss/articles/CBMiwAJBVV95cUxNNUxRcVNWNmdmQVEyMmpId1VIVURWLU10SWJIOGVUZFE0czBpVUFtTkRwcnpJVVczdXZqN0VEd2c2cmxZNUFhRjJuUklnaXo4TkFSV3h4RTcwa1l4OXZKakxEaTNiZjlYLVNleXlTcW1iOXoyQjVwOVJyZFIyS3pGalhYU1VBWElua3h2dWM2MDZlV19OV1JSUFdzRFpNaFdYekN5ZXNwWkcyVl9iYXIzZkFxdWs1aHM5ZEQ4WHlKb3ljd2ZqdE05UjVPNDl4ZWduNnBLVjlBRjhvV01tN3JGT2QzMC1menYtc0FNZ3ZmeF82cDFBTEtGZjFFeklwX2ctcGhWXzVqSW5VYTQzcTdQZ0pFc0RaejZtMFFscGhCb0FLXzZKQVl0eXRLcmxsY2ZqMVdETUtLcU1xT0ViUmI1Tg?oc=5
Symbol: (IONS)
Published: 2026-09-22 03:00:00 EDT
Time precision: minute
Title: Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - BioSpace

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
BioSpace